In the last decade, lung transplantation has become an accepted therapy for end-stage lung disease. In the present study, we investigated the pattern of inflammatory cells in BAL fluid, their corresponding activation markers in serum and BAL fluid, including levels of circulating CAMs from patients who have undergone lung transplantation. The aim of the study was to investigate whether any of these variables were increased during acute rejection.
MATERIALS AND METHODS

Design
Retrospective analyses of serum and BAL fluid samples were performed. Differential cell counts of eosinophil granulocytes (EOS), polymorphonuclear granulocytes (PMN), macrophages, and lymphocytes were made from the BAL fluid. The presence of ECP, myeloperoxidase (MPO) , and HYA in serum and BAL fluid were used as indirect markers for activation of EOS, PMN, and fibroblasts, respectively. In addition, levels of circulating ICAM-1, cVCAM-1, and cE-selectin were analyzed.
Subjects
Fifteen patients undergoing single lung (n=9), bilateral lung (n=2), or heart-lung (n=4) transplantation were studied during an interval of 2 to 60 wveeks. For patient data, see Table 1 . The serum and BAL fluid samples were obtained for a different study that had been approved by the ethical committee of University of Goteborg. All subjects gave their written and oral consent. Donors and recipients were matched for cytomiegalovirus (CMV) serologic status. All organs were harvested in a similar fashion.
Immunosuppression
Patients received immunosuppressants preoperatively with a loading dose of cyclosporine (6 to 8 mg/kg) and azathioprine (4 mg/kg) orally. Postoperatively, rabbit antithymocyte globulin (Pasteur Merieux; 2.5 mg/kg) was used for induction immunosuppression on 3 to 5 consecutive days. Methylprednisolone was given IV (500 mg at perfusion followed by 125 mg every v hx3) and continued by enteral adnministration of prednisone, 0.3 mg/kg/d, tapered to 0.2 mg/kg/d, 1 month postoperatively.
Cyclosporine was given betxveen 12 and 24 h after transplantation by continuous IV infusion at a dosage adjusted to maintain a serum level of 300 to 400 pg/L (radioimmunoassay [RIA] specific for whole blood; Cytotrac; Incstar; Stillwater, Minn). As soon as enteral function was normalized, cyclosporine was administered orally. Azathioprine was given orally once a day (2 mg/kg) and adjusted to maintain an absolute number of blood neutrophils of 3 to 5x106 cm3.
Episodes of acute rejection were treated w,ith mnethylprednisolone (1 g IV) for 3 days, and antithymocyte globulin therapy was reinstituted if rejection was resistant to steroid treatment.
Postoperative Follow-up Transbronchial biopsies (TBBs) and BAL were performed routinely at 2 and 4 weeks after transplantation, and thereafter monthly for the first 3 months. Additional bronchoscopywith TBBs and BAL vere performed after 6, 9, and 12 months postoperatively, or whenever indicated by clinical parameters such as dyspnea, hypoxemia, decline in FEV1 values, radiographic infiltrate, or unexplained fever. Repeated TBBs and BAL were performed approximately 4 weeks after treatment of rejection episodes. Patients were anesthetized for bronchoscopy with propofol IV, and supplemental 100% oxygen was delivered nasally at a rate of 4 to 5 Jimin with blood oxygen saturation continually monitored vith a pulse oximeter (Ohmeda; Louisville, Ky). Kentucky). Flexible fiberoptic bronchoscopes (Olympus; Lake Success, NY) of various models were used.
The histopathologic diagnosis of rejection was determined by TBB and graded according to the intemational working formulation for classification and grading of pulmonary rejection.2 BAL analysis included direct microscopy for CMV, Pneumncystis carinii, fungi, and mycobacteria. In addition, immunofluorescence microscopy for P carinii, Legionella pneunwphilia, and respiratory syncytial virus was performed, and polymerase chain reaction for CMV, cultures for bacteria, including Legionella and mycobacteria, fungi, and virus were analyzed. 
RESULTS
There were no deaths during the study period. Bronchoscopies with concurrent TBB and BAL were performed on 38 different occasions. Eleven patients were studied at least twice (mean, 3.1; range, 2 to 5 per patient), 2 to 60 weeks after transplantation. In four patients, samples were from one occasion only, and on seven occasions BAL fluid, but not serum samples, was taken. There were 22 histopathologically diagnosed rejection episodes (58%), and of these 7 were minimal (A 1), 13 were mild (A 2), and 2 were rejection episodes of moderate (A 3) character. No episode of severe rejection was diagnosed.
The results are presented as sampling episodes with regard to characterization ofrejection. Two episodes of bacterial infection, one episode with CMV pneumonitis, and one with respiratory syncytial virus pneumonitis were diagnosed. (Fig 3) . The two patients with moderate acute rejection (A 3) had intermediate values of ECP, HYA and MPO (Fig 1-3) . The BAL albumin levels were comparable in all four groups (Fig 4) .
The levels of cICAM-1 in BAL fluid were not statistically different between the rejection groups (Fig 4) . BAL VCAM-1 and BAL cE-selectin were all below the detection limit of 2 pg/L (data not shown). In serum, levels of all three cCAMs were measurable, but the mean levels did not differ statistically between the groups (Table 3) . Rejection (n=22) compared to no rejection (n=12) showed no differences in levels of inflammatory markers, cCAMs, or albumin (Table 2) .
Episodes with bacterial and viral infection were few, and these results were analyzed separately from the rejection episodes (Table 2) .
The serum levels of ECP, HYA, and cCAMs did not differ statistically between the groups ( The patients with mild acute rejection (A 2) had significantly higher mean percentage of eosinophils (p<0.05) compared to the group wvith minimal rejection (A 1) (Fig 1) . Neither the mean percentage of neutrophils (Fig 3) 
DISCUSSION
This retrospective study in patients who have undergone lung transplantation shows that activation of eosinophils and fibroblasts assessed by ECP and HYA in BAL fluid is present during mild acute rejection of the allograft. The percentage of eosinophils is also increased. Increased activation ofneutrophils or changes in neutrophil percentage are not apparent. The findings are in agreement with earlier reports in which increased percentage of eosinophils and signs of eosinophil activation have been found both in acute kidney and liver allograft rejection,3-5"12 and eosinophilia has been monitored in blood and urine to support the rejection diagnosis.6-8 To our knowledge, this is the first study reporting increased ECP levels and allograft eosinophilia during acute rejection of human transplanted lungs.
The eosinophil can release potent cytotoxic granule products that have been associated with the cellular damage seen in a variety of inflammatory diseases, including bronchial asthma.30 32 Several studies have hypothesized that the eosinophil could act as an effector-cell in the inflammation observed during acute graft rejection.3611 Pathogenetically, the eosinophilia could be triggered by release ofcytokines such as interleukin-3 (IL-3) and IL-5 from activated helper T cells, and IL-1 from antigen-presenting macrophages in the allograft.5'8 Eosinophilia is found early in the rejection process, and it is reversed promptly with the standard high-dose steroid rejection treatment. 3'11 From our data, the levels of ECP in BAL fluid appear to reflect eosinophil activity better than serum levels. Increased serum ECP level was found during acute rejection compared to no rejection, but there were no differences between the subgroups as found in the BAL fluid samples. Our interpretation is that the eosinophil activation is largely a local process in the rejecting lung, rather than a systemic one. Increased levels of HYA, which have been found in patients with kidney and liver transplants during acute rejection, are associated with the interstitial edema seen in the allograft tissue.13"15 It is known that HYA, a molecule with unique water-binding properties, may be produced by activated fibroblasts in response to macrophage-released mediators such as tumor necrosis factor-a, tumor necrosis factor-r, and IL-1.3334 It is presumable that HYA and possibly fibroblast activation can be involved in the edema present in rejecting lung allografts.
No significant increase in levels of MPO was found, even if a trend toward increasing values with severity of rejection was present. The incidence of bacterial infection during the study period was too low to evaluate if it affected the levels of MPO. Patients with chronic bronchitis, an inflammatory airway disease characterized by neutrophil activation, have increased levels in bronchial lavage. 35 Chronic, but not acute, lung rejection has been associated with increased numbers of neutrophils,36 but the activation status of the cells involved is not known.
Notably, the almost consistent pattern in our study of increasing ECP and HYA levels with more severe rejection is disturbed by the two episodes of moderate rejection (A 3) with intermediate values. However, the low number of A 3 episodes makes it difficult to evaluate the activity level for both eosinophils and fibroblasts for these episodes. The level of immunosuppression was comparable between the groups.
We found circulating forms of ICAM-1, cVCAM-1, and cE-selectin in serum, but only cICAM-1 was present in BAL fluid. This is consistent with earlier findings from patients with obstructive chronic bronchitis,37 reflecting the fact that VCAM-1 and E-selectin are expressed on endothelial cells, whereas ICAM-1 can be found also on airway epithelial cells.38 In transplantation, increased expression of CAMs has been shown in tissue samples during rejection.21 '22 Only cICAM-1 of the circulating forms has been studied in connection with rejection, and conflicting reports exist regarding the value of this molecule as a marker. One study on patients who had undergone liver transplantation found evidence of local release of cICAM-1 in bile during rejection, but serum levels were not specific since they were elevated also in infection.24 A second study on heart transplant recipients found no correlation ofserum cICAM-1 with endomyocardial biopsy scores, although high levels were associated with poor survival.39 In contrast, a study on kidney transplant recipients found increased serum cICAM-1 levels in connection with acute rejection, and irreversible graft rejection showed persistently elevated levels. 
